CaltechAUTHORS
  A Caltech Library Service

Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer

Gaur, Shikha and Chen, Linling and Yen, Terence and Wang, Yafan and Zhou, Bingsen and Davis, Mark and Yen, Yun (2012) Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer. Nanomedicine-Nanotechnology Biology and Medicine, 8 (5). pp. 721-730. ISSN 1549-9634. doi:10.1016/j.nano.2011.09.007. https://resolver.caltech.edu/CaltechAUTHORS:20120724-104817503

Full text is not posted in this repository. Consult Related URLs below.

Use this Persistent URL to link to this item: https://resolver.caltech.edu/CaltechAUTHORS:20120724-104817503

Abstract

Camptothecin showed remarkable anticancer activity in animal models of cancer but was restricted in clinical use for its adverse toxicity in patients. The preclinical efficacy of CRLX101, a nanoparticle (NP) assembly containing cyclodextrin-based polymer and camptothecin was evaluated by in vitro cytotoxicity in gastric cancer cell lines and in vivo antitumor effects in human gastric cancer cell line BGC823 xenografts. Treated tumor sections were analyzed for presence of NPs and compared with vehicle control tumors for hypoxia and angiogenesis. Gastric cancer cell lines showed high in vitro cytotoxicity for CRLX101 and also showed strong antitumor activity in vivo. Electron micrographs revealed the intracellular presence of NPs in close proximity to vesicles. A significant decrease in expressions of carbonic anhydrase, VEGF, and CD31 proteins in treated tumors indicated an inhibition of hypoxia and angiogenesis. The results provide preclinical data for gastric adenocarcinoma. From the Clinical Editor: This study describes a nanoparticle assembly containing cyclodextrin-based polymer and camptothecin, resulting in increased bioavailability of camptothecin, an effective but toxic anti-cancer agent. The antitumor effects and safety profile were demonstrated in a gastric carcinoma cell line.


Item Type:Article
Related URLs:
URLURL TypeDescription
http://dx.doi.org/10.1016/j.nano.2011.09.007DOIArticle
http://www.sciencedirect.com/science/article/pii/S1549963411003649PublisherArticle
ORCID:
AuthorORCID
Davis, Mark0000-0001-8294-1477
Yen, Yun0000-0003-0815-412X
Additional Information:© 2012 Elsevier Inc. Received 8 March 2011. Accepted 22 September 2011. Available online 25 October 2011. The funding for the study was provided by the City of Hope internal funds to Dr. Yun Yen. We thank Dr. David Ann for helpful suggestions; Dr. Li Zhuo, Ms. Sofia Loera, and Ms. Mariko Lee for their help with electron microscopy, histopathological staining, and light microscope imaging, respectively; and Mr. Vincent Ann for editing the manuscript.
Funders:
Funding AgencyGrant Number
City of HopeUNSPECIFIED
Subject Keywords:Camptothecin; Polymer conjugate; CPT-11; Gastric cancer; Immunohistochemistry; Nanoparticle
Issue or Number:5
DOI:10.1016/j.nano.2011.09.007
Record Number:CaltechAUTHORS:20120724-104817503
Persistent URL:https://resolver.caltech.edu/CaltechAUTHORS:20120724-104817503
Official Citation:Shikha Gaur, Linling Chen, Terence Yen, Yafan Wang, Bingsen Zhou, Mark Davis, Yun Yen, Preclinical study of the cyclodextrin-polymer conjugate of camptothecin CRLX101 for the treatment of gastric cancer, Nanomedicine: Nanotechnology, Biology and Medicine, Volume 8, Issue 5, July 2012, Pages 721-730, ISSN 1549-9634, 10.1016/j.nano.2011.09.007.
Usage Policy:No commercial reproduction, distribution, display or performance rights in this work are provided.
ID Code:32674
Collection:CaltechAUTHORS
Deposited By: Jason Perez
Deposited On:24 Jul 2012 18:13
Last Modified:09 Nov 2021 21:29

Repository Staff Only: item control page